Stefan Scheiblich

This inventor holds 33 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignees: Hoffmann-La Roche Inc., American Cyanamid Company, Basf Aktiengesellschaft. Active years: 1998-2011.

USPTO Granted Patents = 33 (Patent Applications = 2)

% Patents Active = 60.6

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 86(Granted Patents)

Location History:

Backhaushohol, DE (1999 - 2000)
Mainz, DE (1998 - 2006)
Penzberg, DE (2003 - 2011)

Company Filing History:

14 out of 5,011

Hoffmann-La Roche Inc.

patents

11 out of 3,580

American Cyanamid Company

patents

8 out of 10,754

Basf Aktiengesellschaft

patents

Years Active: 1998-2011

Loading Chart...

Areas of Expertise:

Protein Kinase Inhibitors

Pharmaceutical Agents

Heterocyclic Compounds

Pyridine Derivatives

Herbicidal Compounds

Dihydropyrimido Derivatives

Amino-Substituted Compounds

Antiproliferative Activity

Pyrimidine Derivatives

Carbamate Derivatives

Benzamide Derivatives

Thienyl Pyridines

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8067599 - Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors (2011-11-29),

2. 8058283 - 7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors (2011-11-15),

3. 7786113 - Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents (2010-08-31),

4. 7776878 - Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents (2010-08-17),

5. 7655651 - Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents (2010-02-02),

6. 7618964 - Benzamide derivatives, their manufacture and use as pharmaceutical agents (2009-11-17),

7. 7550589 - 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors (2009-06-23),

8. 7494993 - Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents (2009-02-24),

9. 7226923 - Phthalazinone derivatives (2007-06-05),

10. 7189732 - Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives (2007-03-13),

11. 7169781 - Imidazole derivatives and their use as pharmaceutical agents (2007-01-30),

12. 7163941 - Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents (2007-01-16),

13. 7129351 - Pyrimido compounds having antiproliferative activity (2006-10-31),

14. 7091345 - Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives (2006-08-15),

15. 7008905 - Method of combating undesired plant growth on cereals (2006-03-07),

Title: Celebrating the Innovations of Stefan Scheiblich

Introduction: Stefan Scheiblich, based in Penzberg, Germany, is an esteemed inventor with a remarkable portfolio of 33 patents to his name. His contributions primarily focus on the development of innovative compounds that have significant implications in the medical field, particularly in combating serious illnesses such as cancer.

Latest Patents: Among his latest patents are groundbreaking inventions such as Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors. These patents detail compounds that include their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers, and racemates. The preparation of these compounds and the medicaments that arise from them play a crucial role in the control or prevention of diseases, especially cancer. Another notable patent is for 7H-pyrido[3,4-D]pyrimidin-8-ones, which also emphasizes their manufacture and therapeutic use as protein kinase inhibitors.

Career Highlights: Stefan's professional journey is marked by significant affiliations with renowned companies like Hoffmann-La Roche Inc. and American Cyanamid Company. His work in these establishments has paved the way for numerous advancements in pharmaceutical innovations, demonstrating his dedication to enhancing healthcare through science.

Collaborations: Throughout his career, Stefan has collaborated with brilliant minds, including Thomas Maier and Helmut Siegfried Baltruschat. Together, they have pushed the boundaries of research and innovation, leading to advancements that benefit society.

Conclusion: Stefan Scheiblich stands out as a prolific inventor whose work is shaping the future of healthcare. With a solid foundation of patents and collaborations, he continues to inspire the next generation of innovators and researchers in the field of pharmaceuticals. His contributions are invaluable, and the impact of his inventions will be felt for years to come.